A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.

Sponsor
Novo Nordisk A/S
Study ID
NCT02717858
Phase
PHASE1
Status
Completed

Conditions

  • Metabolism and Nutrition Disorder
  • Obesity

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached.
  • placebo — DRUG
    Injected s.c./subcutaneously (under the skin) once daily.

Study Details

This trial is conducted in Europe. The aim of this trial is to investigate the effects of liraglutide on gallbladder emptying in overweight and obese subjects.

Key Dates

Start date
Mar 16, 2016
Status verified
Jun 2018
Primary completion
Feb 27, 2017
Completion
Feb 27, 2017

Study Design

Enrollment
52 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide
  • Placebo Comparator: Placebo

Primary Outcome Measure

Maximum postprandial gallbladder ejection fraction (GBEFmax) [ Time Frame: At 12 weeks (visit 9) ]

Related Studies